Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Asset Writedowns and Impairment (2018 - 2025)

TELA Bio (TELA) has 8 years of Asset Writedowns and Impairment data on record, last reported at $632000.0 in Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment fell 3.51% year-over-year to $632000.0; the TTM value through Sep 2025 reached $2.9 million, up 47.81%, while the annual FY2024 figure was $3.0 million, 108.98% up from the prior year.
  • Asset Writedowns and Impairment reached $632000.0 in Q3 2025 per TELA's latest filing, up from $280000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $1.4 million in Q4 2024 and bottomed at $57000.0 in Q4 2022.
  • Average Asset Writedowns and Impairment over 5 years is $485052.6, with a median of $560000.0 recorded in 2024.
  • Peak YoY movement for Asset Writedowns and Impairment: tumbled 72.38% in 2021, then skyrocketed 640.35% in 2023.
  • A 5-year view of Asset Writedowns and Impairment shows it stood at $105000.0 in 2021, then plummeted by 45.71% to $57000.0 in 2022, then surged by 640.35% to $422000.0 in 2023, then surged by 229.86% to $1.4 million in 2024, then crashed by 54.6% to $632000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $632000.0 in Q3 2025, $280000.0 in Q2 2025, and $630000.0 in Q1 2025.